Rosiglitazone decreases albuminuria in type 2 diabetic patients

Kidney International

Volumn 72, Issue 11, 2007, Pages 1367-1373

  Miyazaki, Y ^a   Cersosimo, E ^a   Triplitt, C ^a   DeFronzo, R A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adipocytokines; Albuminuria; Insulin resistance; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALBUMIN; CREATININE; FATTY ACID; GLUCOSE; INSULIN; PLACEBO; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; KIDNEY DISEASE; LINEAR REGRESSION ANALYSIS; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE BLIND PROCEDURE;

EID: 36249006990     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002516     Document Type: Article

References (35)

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
2. Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes FFA and ectopic fat in the pathogenesis of type 2 diabetes mellitus. PPAR agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478.
3. Guan Y, Breyer M. Peroxisome proliferator-activated receptors (PPARs). Novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30.
4. Asano T, Wakisaka M, Yoshinari M et al. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 2000; 1497: 148-154.
5. Ishiki K, Haneda M, Koya D et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulinsensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032.
6. McCarthy KJ, Routh RE, Shaw W et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000; 58: 2341-2350.
7. Iwano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
8. Bakris G, Viberti G, Weston WM et al. Rosglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
9. Moriwaki Y, Yamamoto T, Shibutani Y et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003; 52: 605-608.
10. Kalantarinia K, Awad AS, Siragy H. Urinary and renal interstitial concentrations of TNF-α increase prior to albuminuria in diabetic rats. Kidney Int 2003; 64: 1208-1213.
11. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-2568.
12. Prabhakar S. Role of nitric oxide in diabetic nephropathy. Sem Nephrol 2004; 24: 333-344.
13. Stehouwer CDA, Henry RMA, Dekker JM et al. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction. Kidney Int 2004; 66: S42-S44.
14. Yu Y, Suo L, Yu H et al. Insulin resistance and endothelial dysfunction in type 2 diabetic patients with or without microalbuminuria. Diabetes Res Clin Pract 2004; 65: 95-104.
15. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16: 952-958.
16. Groop L, Ekstrand A, Forsblom C et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin- dependent) diabetes mellitus. Diabetologia 1993; 36: 642-647.
17. Mayerson AB, Hundal S, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
18. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients. Diabetes 2003; 52: 1943-1950.
19. Nakamura T, Fukui M, Ebihara I et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-456.
20. Hasegawa G, Nakano K, Sawada M et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012.
21. Trachtman H, Futterweit S, Crimmins DL. High glucose inhibits nitric oxide production in cultured rat mesangial cells. J Am Soc Nephrol 1997; 8: 1276-1282.
22. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46: 1543-1549.
23. Chen H, Montagnani M, Shimomura I, Quon MJ. Adiponectin stimulates nitric oxide production in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
24. Tiikkainen M, Hakkinen AM, Nyman T et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
25. Miyazaki Y, Mahankali A, Wajcberg E et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-4319.
26. Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
27. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215-222.
28. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104.
29. Civaterese AE, Ukropcova B, Carling S et al. Role for adiponectin in human skeletal muscle bioenergetics. Cell Metab 2006; 4: 75-87.
30. Itani SI, Ruderman NB, Schneider F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C and IκB-α. Diabetes 2002; 51: 2005-2011.
31. Ellis BA, Poynten A, Lowy AJ et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 2000; 279: E554-E560.
32. Satoh H, Nguyen MT, Trujillo M et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 2005; 54: 1304-1313.
33. Bonora E, Del Prato S, Bonadonna RC et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 1992; 41: 1151-1159.
34. DeFronzo RA, Tobin JD, Anders R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
35. Hume R, Weyers E. Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol 1971; 24: 234-238.